The combination of Aspirion and Advicare will further reinforce market leadership in clinical denials and provide the new organization’s combined hospital system clients with expanded capabilities to support a broader array of denied claims. The companies’ shared vision and cultural synergy that focus on customer centricity, innovation, and delivering superior solutions will facilitate optimal revenue recovery performance and financial success for their healthcare provider partners.

The Advicare management team is led by Stacy Gearhart and Gloriann Sordo, co-founders of the company. “This is an exciting time for Advicare and our client partners. We are thrilled to be a part of the Aspirion team,” said Sordo. “Together, as Aspirion, we are well-positioned to continue to grow and support our provider partners in their revenue recovery efforts as well as provide expanded career opportunities to our employees.”

“Aspirion’s focus on delivering solutions that exceed hospital systems’ other alternatives is central to all we do,” stated Jason Erdell, CEO of Aspirion. “We continue to invest heavily in contemporary technologies, human resources, and improved claims resolution to produce uncommon results. This is evidenced by our number one revenue integrity ranking of 96.6 by KLAS Research and a client retention rate of more than 97 percent. In Advicare, we found a partner that shares our commitment to produce the best results and client experience possible. We have long admired the innovative approach Advicare utilizes to address a broad array of clinical denials. Today’s combination allows both organizations to service more completely the wide range of denied claims of our collective clients.”

“Today’s announcement reinforces our commitment to strengthening and expanding our suite of healthcare revenue cycle management offerings,” said Kevin Barrett, Chairman of the Board of Aspirion. “The addition of Advicare builds on our strong track record of leadership and deep capabilities in healthcare revenue recovery, providing clear and immediate value to our provider partners, and ultimately, to our employees and investors.”

This marks Aspirion’s fourth transaction in the last three years and further expands the services the Company provides to its clients. The Company’s mergers and acquisitions (M&A) and strategic partnership plan is complemented by a track record of new client wins and service expansion within existing clients. As reflected in a recently released KLAS survey, Aspirion received one of the highest rankings among healthcare RCM vendors in customer service. As an independent research firm, KLAS Research states it has delivered accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996.

Aspirion was advised by McDermott Will & Emery LLP, Grant Thornton LLP, Lockton Companies LLC, and Opus Advisory. To learn more about Aspirion, please visit www.aspirion.com.